JP2013518605A5 - - Google Patents

Download PDF

Info

Publication number
JP2013518605A5
JP2013518605A5 JP2012552933A JP2012552933A JP2013518605A5 JP 2013518605 A5 JP2013518605 A5 JP 2013518605A5 JP 2012552933 A JP2012552933 A JP 2012552933A JP 2012552933 A JP2012552933 A JP 2012552933A JP 2013518605 A5 JP2013518605 A5 JP 2013518605A5
Authority
JP
Japan
Prior art keywords
modified
sugar
nucleoside
modified oligonucleotide
wing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012552933A
Other languages
English (en)
Japanese (ja)
Other versions
JP6018506B2 (ja
JP2013518605A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/024104 external-priority patent/WO2011097644A2/en
Publication of JP2013518605A publication Critical patent/JP2013518605A/ja
Publication of JP2013518605A5 publication Critical patent/JP2013518605A5/ja
Application granted granted Critical
Publication of JP6018506B2 publication Critical patent/JP6018506B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012552933A 2010-02-08 2011-02-08 対立遺伝子多様体の選択的低減 Active JP6018506B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30245810P 2010-02-08 2010-02-08
US61/302,458 2010-02-08
US37164010P 2010-08-06 2010-08-06
US61/371,640 2010-08-06
PCT/US2011/024104 WO2011097644A2 (en) 2010-02-08 2011-02-08 Selective reduction of allelic variants

Publications (3)

Publication Number Publication Date
JP2013518605A JP2013518605A (ja) 2013-05-23
JP2013518605A5 true JP2013518605A5 (enExample) 2014-03-27
JP6018506B2 JP6018506B2 (ja) 2016-11-02

Family

ID=44356119

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012552933A Active JP6018506B2 (ja) 2010-02-08 2011-02-08 対立遺伝子多様体の選択的低減

Country Status (7)

Country Link
US (5) US9006198B2 (enExample)
EP (3) EP3208347B1 (enExample)
JP (1) JP6018506B2 (enExample)
AU (1) AU2011213563B2 (enExample)
CA (1) CA2789038A1 (enExample)
IL (1) IL221271A (enExample)
WO (1) WO2011097644A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101881596B1 (ko) 2008-12-02 2018-07-24 웨이브 라이프 사이언시스 재팬 인코포레이티드 인 원자 변형된 핵산의 합성 방법
RU2612521C2 (ru) 2009-07-06 2017-03-09 Онтории, Инк. Новые пролекарства нуклеиновых кислот и способы их применения
EP3321361B1 (en) * 2010-02-08 2019-03-27 Ionis Pharmaceuticals, Inc. Selective reduction of allelic variants
JP5868324B2 (ja) 2010-09-24 2016-02-24 株式会社Wave Life Sciences Japan 不斉補助基
WO2012109395A1 (en) * 2011-02-08 2012-08-16 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
BR112014001244A2 (pt) 2011-07-19 2017-02-21 Wave Life Sciences Pte Ltd métodos para a síntese de ácidos nucléicos funcionalizados
EP3205725B1 (en) 2011-08-11 2019-03-27 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
WO2013159108A2 (en) 2012-04-20 2013-10-24 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
CN112007045A (zh) 2012-07-13 2020-12-01 波涛生命科学有限公司 手性控制
ES2862073T3 (es) 2012-07-13 2021-10-06 Wave Life Sciences Ltd Grupo auxiliar asimétrico
BR112015000723A2 (pt) 2012-07-13 2017-06-27 Shin Nippon Biomedical Laboratories Ltd adjuvante de ácido nucléico quiral
US9695418B2 (en) 2012-10-11 2017-07-04 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleosides and uses thereof
EP2906255B1 (en) * 2012-10-12 2023-02-22 Ionis Pharmaceuticals, Inc. Antisense compounds and uses thereof
US20150275208A1 (en) 2012-10-12 2015-10-01 Isis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
EP3778618A1 (en) * 2013-02-04 2021-02-17 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
ES2754177T3 (es) 2013-06-12 2020-04-16 Massachusetts Gen Hospital Métodos para la detección multiplexada de moléculas diana y sus usos
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
EP3095460A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
EP3095459A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
CN113278617A (zh) 2014-01-16 2021-08-20 波涛生命科学有限公司 手性设计
MA43331A (fr) * 2014-10-17 2017-08-23 Nogra Pharma Ltd Procédés et compositions pour le traitement d'un sujet au moyen d'un oligonucléotide antisens de smad7
MA43072A (fr) 2015-07-22 2018-05-30 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
EA201800367A1 (ru) 2015-12-10 2019-02-28 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения болезни хантингтона
MA45270A (fr) 2016-05-04 2017-11-09 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
KR20200033249A (ko) 2017-06-05 2020-03-27 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료 화합물
CA3067591A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
US11395822B2 (en) 2017-06-28 2022-07-26 Ptc Therapeutics, Inc. Methods for treating Huntington's disease
CN110996968A (zh) * 2017-08-08 2020-04-10 波涛生命科学有限公司 寡核苷酸组合物及其方法
US12103926B2 (en) 2018-03-27 2024-10-01 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
BR112020026545A2 (pt) 2018-06-27 2021-03-23 Ptc Therapeutics, Inc. Compostos heterocíclicos e de heteroarila para o tratamento da doença de huntington
EA202092899A1 (ru) 2018-06-27 2021-05-14 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Гетероарильные соединения для лечения болезни гентингтона
WO2020117706A1 (en) 2018-12-03 2020-06-11 Triplet Therapeutics, Inc. Methods for the treatment of trinucleotide repeat expansion disorders associated with mlh3 activity
CA3126845A1 (en) * 2019-02-01 2020-08-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
AU2020377204A1 (en) 2019-11-01 2022-06-02 Novartis Ag The use of a splicing modulator for a treatment slowing progression of huntington's disease
US20220251557A1 (en) * 2019-11-27 2022-08-11 Tokyo Institute Of Technology Method for reducing toxicity of antisense nucleic acids
JP2023526533A (ja) 2020-05-22 2023-06-21 ウェイブ ライフ サイエンシズ リミテッド 二本鎖オリゴヌクレオチド組成物及びそれに関連する方法
AR122534A1 (es) 2020-06-03 2022-09-21 Triplet Therapeutics Inc Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
TW202241462A (zh) * 2021-01-29 2022-11-01 美商Ionis製藥公司 調節杭丁頓蛋白(huntingtin)之化合物及方法
TW202304446A (zh) 2021-03-29 2023-02-01 瑞士商諾華公司 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途
EP4665359A2 (en) * 2023-02-17 2025-12-24 Ionis Pharmaceuticals, Inc. Allele-selective compounds and methods for modulating huntingtin expression
WO2025015335A1 (en) 2023-07-13 2025-01-16 Korro Bio, Inc. Rna-editing oligonucleotides and uses thereof
WO2025128799A1 (en) 2023-12-12 2025-06-19 Korro Bio, Inc. Double-stranded rna-editing oligonucleotides and uses thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2699808A (en) 1944-10-06 1955-01-18 Mark W Lowe Apparatus for peeling tomatoes
US2699508A (en) 1951-12-21 1955-01-11 Selectronics Inc Method of mounting and construction of mounting for low frequency piezoelectric crystals
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
JPH08504559A (ja) 1992-12-14 1996-05-14 ハネウエル・インコーポレーテッド 個別に制御される冗長巻線を有するモータシステム
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5656408A (en) 1996-04-29 1997-08-12 Xerox Corporation Coated carrier particles
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
AU9063398A (en) 1997-09-12 1999-04-05 Exiqon A/S Oligonucleotide analogues
US20030228597A1 (en) 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
US6753422B2 (en) * 1999-03-01 2004-06-22 O'brien Thomas G. Odc allelic analysis method for assessing carcinogenic susceptibility
WO2000052210A2 (en) * 1999-03-01 2000-09-08 Variagenics, Inc. Methods for targeting rna molecules
AU776362B2 (en) 1999-05-04 2004-09-09 Roche Innovation Center Copenhagen A/S L-ribo-LNA analogues
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
WO2001079283A1 (en) 2000-04-13 2001-10-25 University Of British Columbia Modulating cell survival by modulating huntingtin function
EP1499627A2 (en) 2001-07-03 2005-01-26 ISIS Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
AU2002326589B2 (en) 2001-08-07 2008-06-05 University Of Delaware Compositions and methods for the prevention and treatment of Huntington's disease
AU2003291753B2 (en) 2002-11-05 2010-07-08 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
EP2957568B1 (en) 2002-11-05 2016-12-21 Ionis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
EP2213738B1 (en) 2002-11-14 2012-10-10 Dharmacon, Inc. siRNA molecules targeting Bcl-2
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
ATE555118T1 (de) 2003-08-28 2012-05-15 Takeshi Imanishi Neue synthetische nukleidsäuren vom typ mit quervernetzter n-o-bindung
JP5379347B2 (ja) 2003-09-18 2013-12-25 アイシス ファーマシューティカルズ, インコーポレーテッド 4’−チオヌクレオシドおよびオリゴマー化合物
US20050176045A1 (en) * 2004-02-06 2005-08-11 Dharmacon, Inc. SNP discriminatory siRNA
CA2569419A1 (en) * 2004-06-03 2005-12-22 Isis Pharmaceuticals, Inc. Double strand compositions comprising differentially modified strands for use in gene modulation
EP1799859B1 (en) 2004-09-17 2014-07-02 Isis Pharmaceuticals, Inc. Enhanced antisense oligonucleotides
ATE522626T1 (de) 2005-06-28 2011-09-15 Medtronic Inc Verfahren und nukleotid-sequenzen, die bevorzugt die expression eines mutierten huntingtin-genes unterdrücken
WO2007089611A2 (en) * 2006-01-26 2007-08-09 Isis Pharmaceuticals Inc. Compositions and their uses directed to huntingtin
EP1984381B1 (en) 2006-01-27 2010-09-29 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
WO2007131237A2 (en) * 2006-05-05 2007-11-15 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of ptp1b
ES2389737T3 (es) 2006-05-11 2012-10-31 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos modificados en 5'
US9273356B2 (en) 2006-05-24 2016-03-01 Medtronic, Inc. Methods and kits for linking polymorphic sequences to expanded repeat mutations
EP2046993A4 (en) 2006-07-07 2010-11-17 Univ Massachusetts RNA SILENCING COMPOSITIONS, AND METHODS OF TREATING HUNTINGTON CHOREA
EP2410053B2 (en) 2006-10-18 2020-07-15 Ionis Pharmaceuticals, Inc. Antisense compounds
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
KR20090103894A (ko) 2006-11-27 2009-10-01 아이시스 파마수티컬즈 인코포레이티드 고콜레스테롤혈증을 치료하는 방법
EP2125852B1 (en) 2007-02-15 2016-04-06 Ionis Pharmaceuticals, Inc. 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
WO2008143774A2 (en) 2007-05-01 2008-11-27 University Of Massachusetts Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy
US8278425B2 (en) 2007-05-30 2012-10-02 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
DK2173760T4 (en) 2007-06-08 2016-02-08 Isis Pharmaceuticals Inc Carbocyclic bicyclic nukleinsyreanaloge
EP2014769B1 (en) 2007-06-18 2010-03-31 Commissariat à l'Energie Atomique Reversible siRNAa-based silencing of mutated and endogenous wild-type huntingtin gene and its application for the treatment of Huntington's disease
US8278283B2 (en) 2007-07-05 2012-10-02 Isis Pharmaceuticals, Inc. 6-disubstituted or unsaturated bicyclic nucleic acid analogs
CA2726866A1 (en) 2008-05-09 2009-11-12 The University Of British Columbia Methods and compositions for the treatment of huntington's disease
AT507215B1 (de) 2009-01-14 2010-03-15 Boehler Edelstahl Gmbh & Co Kg Verschleissbeständiger werkstoff
US9778706B2 (en) 2012-02-24 2017-10-03 Blackberry Limited Peekable user interface on a portable electronic device
US9984408B1 (en) 2012-05-30 2018-05-29 Amazon Technologies, Inc. Method, medium, and system for live video cooperative shopping

Similar Documents

Publication Publication Date Title
JP2013518605A5 (enExample)
JP2016171800A5 (enExample)
JP7354342B2 (ja) タウ発現を調節するための組成物
JP7194222B2 (ja) アタキシン2の発現を調節するための組成物
JP6652984B2 (ja) 対立遺伝子多様体の選択的低減
Van Rooij et al. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles
CA2831915C (en) Modulation of signal transducer and activator of transcription 3 (stat3) expression
JP2013226147A5 (enExample)
JP2013516489A5 (enExample)
JP2015536132A5 (enExample)
JP2020022483A (ja) C9orf72発現を調節するための組成物
JP2016530882A5 (enExample)
JP2012029693A5 (enExample)
JP2014511686A5 (enExample)
JP2009506124A5 (enExample)
JP2016533765A5 (enExample)
JP2015502365A5 (enExample)
JP2014530004A5 (enExample)
WO2011097644A3 (en) Selective reduction of allelic variants
JP2016533751A5 (enExample)
BR112016021848B1 (pt) Composto antissenso ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos dos mesmos
JP2012050438A5 (enExample)
JP2013518604A5 (enExample)
CN104968783A (zh) 用于调节c9orf72表达的组合物
JP2010530239A5 (enExample)